Capital Expenditures for Edwards Lifesciences (EW)
According to Edwards Lifesciences's latest reported financial statements, the company's current capital expenditures (TTM) is $260.20M USD. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingCapital ExpendituresSwitch metric
Latest period
$260.20M
YoY change
+3.1%
5Y CAGR
-8.6%
Peak year (2020)
$407.30M
Cumulative capital expenditures
$3.84B
CapEx history chart for Edwards Lifesciences (EW) from 1999 to 2025
CapEx history table for Edwards Lifesciences (EW) from 1999 to 2025
| Fiscal year | Period ended | Reported | Capital Expenditures | YoY |
|---|---|---|---|---|
| 2025 | $260.20M | +3.1% | ||
| 2024 | $252.40M | -5.2% | ||
| 2023 | $266.30M | +0.6% | ||
| 2022 | $264.80M | -19.7% | ||
| 2021 | $329.80M | -19.0% | ||
| 2020 | $407.30M | +46.3% | ||
| 2019 | $278.40M | +15.2% | ||
| 2018 | $241.70M | +37.7% | ||
| 2017 | $175.50M | -19.3% | ||
| 2016 | $217.40M | +104.1% | ||
| 2015 | $106.50M | +13.7% | ||
| 2014 | $93.70M | -14.9% | ||
| 2013 | $110.10M | -13.8% | ||
| 2012 | $127.70M | +40.9% | ||
| 2011 | $90.60M | +43.8% | ||
| 2010 | $63.00M | -1.6% | ||
| 2009 | $64.00M | -17.9% | ||
| 2008 | $78.00M | +24.8% | ||
| 2007 | $62.50M | +5.2% | ||
| 2006 | $59.40M | +22.5% | ||
| 2005 | $48.50M | +14.1% | ||
| 2004 | $42.50M | +12.1% | ||
| 2003 | $37.90M | -6.9% | ||
| 2002 | $40.70M | +7.1% | ||
| 2001 | $38.00M | -17.4% | ||
| 2000 | $46.00M | +9.5% | ||
| 1999 | $42.00M | — |
CapEx values are taken from Edwards Lifesciences's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Edwards Lifesciences (EW) most recent annual capital expenditures stands at $260.20M (2025) – edged up 3.1% year-over-year.
Edwards Lifesciences capital expenditures compound annual growth for the 2020–2025 (5 years) window is -8.6%, with a net decline across the window.
Between 2020 and 2025, Edwards Lifesciences capital expenditures plunged 36.1%, falling from $407.30M to $260.20M.
$407.30M stands as the all-time-high annual capital expenditures, posted in 2020, against a low of $37.90M during 2003.
Edwards Lifesciences (EW) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $3.87B.
Edwards Lifesciences Capital Expenditures by Year
Edwards Lifesciences Capital Expenditures 2025: $260.20M
Edwards Lifesciences capital expenditures in 2025 was $260.20M, edged up 3.1% from 2024.
Edwards Lifesciences Capital Expenditures 2024: $252.40M
Edwards Lifesciences capital expenditures in 2024 was $252.40M, declined 5.2% below 2023.
Edwards Lifesciences Capital Expenditures 2023: $266.30M
Edwards Lifesciences capital expenditures in 2023 was $266.30M, edged up 0.6% from 2022.
Edwards Lifesciences Capital Expenditures 2022: $264.80M
Edwards Lifesciences capital expenditures in 2022 was $264.80M, declined 19.7% below 2021.
Edwards Lifesciences Capital Expenditures 2021: $329.80M
Edwards Lifesciences capital expenditures in 2021 was $329.80M.
See more financial history for Edwards Lifesciences (EW).
Sector peers — CapEx
Companies in the same sector as Edwards Lifesciences, ranked by their latest capital expenditures.
| Company | Capital Expenditures | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $90.11B | Healthcare |
| Eli Lilly and Company (LLY) | $7.84B | Healthcare |
| Johnson & Johnson (JNJ) | $4.83B | Healthcare |
| Merck & Co., Inc. (MRK) | $4.11B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $3.62B | Healthcare |
| AstraZeneca PLC (AZN) | $2.81B | Healthcare |
| Amgen Inc. (AMGN) | $1.86B | Healthcare |
| AbbVie Inc. (ABBV) | $1.21B | Healthcare |
Frequently asked questions
What is Edwards Lifesciences's capital expenditures?
- Latest reported capital expenditures for Edwards Lifesciences (EW) is $260.20M (period ending December 31, 2025).
How has Edwards Lifesciences capital expenditures changed year-over-year?
- Edwards Lifesciences (EW) capital expenditures changed +3.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Edwards Lifesciences capital expenditures?
- Edwards Lifesciences (EW) capital expenditures compound annual growth rate is -8.6% over the most recent 5 years available.
When did Edwards Lifesciences capital expenditures hit its highest annual value?
- Edwards Lifesciences capital expenditures reached its highest annual value of $407.30M in 2020.
What was Edwards Lifesciences capital expenditures in 2024?
- Edwards Lifesciences (EW) capital expenditures in 2024 was $252.40M.
What was Edwards Lifesciences capital expenditures in 2025?
- Edwards Lifesciences (EW) capital expenditures in 2025 was $260.20M.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
EW Overview
Company profile, financial tools, and key metrics
EW Revenue Counter
Earns $199.88 every second. See per minute, hour, and day.
EW Earnings Counter
Earns $34.65 per second net profit. See per minute, hour, and day.
EW Economic Scale
Exceeds Fiji's GDP. Compare with world economies.
EW What If Invested
What if you had invested $1,000? See historical returns from any date.
EW How It Makes Money
Discover visual breakdown of $6.30B in revenue — where it comes from and where it goes.
EW Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
EW Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
EW Daily Price Character
Balanced · 50.0% historical win rate (green days). Streaks & record days.
EW Buybacks
0.93% TTM buyback yield. Shareholder yield & SBC comparison.
EW Stock Split History
3 splits on record. Dates, ratios, and cumulative multiple.